Passive transfer of collagen XVII-specific antibodies induces sustained blistering disease in adult mice by Mircea TEODOR Chiriac et al.
Chiriac et al. Orphanet Journal of Rare Diseases 2013, 8:17
http://www.ojrd.com/content/8/1/17RESEARCH Open AccessPassive transfer of collagen XVII-specific
antibodies induces sustained blistering disease in
adult mice
Mircea Teodor Chiriac1,2*, Emilia Licarete1,2, Alexandra Gabriela Sas2, Andreea Maria Rados2, Iulia Lupan1,2,
Anca Mirela Chiriac3, Hilda Speth2, Vlad Pop-Vancia2, Iacob Domsa4, Alina Sesarman5, Octavian Popescu1,2,6
and Cassian Sitaru5,7*Abstract
Background: Bullous pemphigoid is a subepidermal blistering disorder associated with tissue-bound and
circulating autoantibodies directed mainly to the hemidesmosomal component collagen XVII. While recapitulating
the main immunopathological features of the human disease, frank skin blistering does not develop in the absence
of skin rubbing in experimental pemphigoid models that have been established in neonatal mice. Moreover, due to
their experimental design they only allow for short-term disease observation. In the present study we aimed to
establish a model that reproduces the frank skin blistering seen in patients and allows for longer observation times.
Methods: Rabbit and sheep antibodies specific to several fragments of collagen XVII were generated and the
purified antibodies were passively transferred into adult mice.
Results: Collagen XVII-specific IgG bound to the basal membrane of the skin and mucous membranes activating
murine complement in vivo. Mice injected with collagen XVII-specific antibodies, in contrast to mice receiving
control antibodies, developed frank skin blistering disease, reproducing human bullous pemphigoid at the clinical,
histological and immunopathological levels. Titres of circulating IgG in the serum of mice correlated with the extent
of the clinical disease. Mice receiving sheep antibodies specific to murine collagen XVII showed an early onset and
a more active disease when compared to litter mates receiving specific rabbit antibodies.
Conclusion: This novel animal model for bullous pemphigoid should facilitate further investigations of the
pathogenesis of bullous pemphigoid and the development of innovative therapies for this disease.
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Bullous pemphigoid (BP) is the most common auto-
immune blistering disease in Western Europe and USA
[1-4]. Immunopathologically, the disease is characterized
by the presence of tissue-bound and circulating auto-
antibodies directed against the dermal-epidermal junc-
tion (DEJ). Antibodies in BP patients mainly recognize
BP180 (bullous pemphigoid antigen of 180kDa) also
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reproduction in any medium, provided the orwith a type II orientation that spans the lamina lucida,
and to a lesser extent BP230 (bullous pemphigoid anti-
gen of 230kDa), an intracellular hemidesmosomal pro-
tein [5-10]. Since these proteins contribute to the tight
anchoring of basal keratinocytes on the underlying basal
membrane, disruption of their function either through
genetic defects or immunopathological mechanisms
results in a dermal-epidermal separation that ultra-
structurally localizes within the lamina lucida [10-15].
The pathogenic relevance of autoantibodies in BP is
supported by compelling evidence: 1) BP autoantibodies
were shown to recruit and activate leukocytes resulting
in dermal-epidermal separation in cryosections of
human skin [16]; 2) Antibodies against mouse [17] andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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when passively transferred into wild-type or CXVII-
humanized mice, respectively; in addition, antibodies to
human type XVII collagen cross the placenta of immu-
nized mice and induce disease in type XVII collagen-
humanized neonates [18]; 3) Transfer of splenocytes
from mice immunized against human type XVII colla-
gen into Rag2−/−/ CXVII-humanized mice results in
sustained immunoglobulin G (IgG) production and BP
phenotype [19]; 4) Autoantibodies in the majority of BP
patients recognize the non-collagenous 16th (NC16)A
domain of BP180/ CXVII and pre-adsorption of patho-
genic sera with NC16A abolished their pathogenic po-
tential both in vivo [15,18] and ex vivo [16].
Despite important advances in disease management over
the last decades, BP is still a disease with one-year mortality
rates of up to 40% [20]. The existence of animal models re-
producing the disease is essential for our understanding of
pathomechanisms with major implications for afflicted
individuals. The most direct approach for reproducing
autoantibody-induced autoimmune diseases in vivo has
been to inject patients’ serum or purified antibodies specific
to culprit autoantigens into healthy individuals. The method
pioneered in the 1950s by the Harrington–Hollingsworth
Experiment wherein Dr. Harrington received blood from
an idiopathic thrombocytopenic purpura patient was first
used to test the hypothesis that platelet destruction was
caused by a factor circulating in the patient’s blood [21,22].
Future studies using the passive transfer of IgG into labora-
tory animals demonstrated the pathogenic effect of anti-
bodies in several diseases, including myasthenia gravis [23],
pemphigus vulgaris [24] and pemphigus foliaceus [25]. Pre-
vious attempts to reproduce BP by this “classical” transfer
of disease through antibodies from patients into experimen-
tal animals were unsuccessful [26-30]. The failure to trans-
fer the disease in mice has been explained by a lack of
reactivity of patients’ autoantibodies with the murine
BP180/ CXVII-specific due to the low degree of homology
between the human and mouse type XVII collagen
[14,15,17,18,31]. A further reason for the lack of pathogen-
icity of pemphigoid patient’s autoantibodies in mice is
related to their significantly weaker capacity of activating
mouse innate immune factors when compared to human
complement and granulocytes [32]. The “alternative” strat-
egy of generating antibodies to the murine form of type
XVII collagen by immunizing rabbits and then transferring
rabbit antibodies into mice [17] has been used successfully
for developing in vivo models for several other autoimmune
diseases such as pemphigus vulgaris [33], anti-epiligrin cica-
tricial pemphigoid [34], and epidermolysis bullosa acquisita
[35]. Among these, the neonatal BP models have some
major shortcomings including the fact that frank skin blis-
tering does not occur and the very short observation times
that precludes adequately dissecting disease pathogenesisand developing therapeutic strategies. In the present study,
we aimed at addressing these shortcomings by developing a
novel passive transfer model for bullous pemphigoid in
adult mice. We generated antibodies against the murine
BP180/ CXVII by immunizing rabbit and sheep with re-
combinant forms of the murine antigen. After being pas-
sively injected into adult wild type mice, these antibodies
bound to the DEJ, activated complement and recruited in-
flammatory cells resulting in tissue damage. The phenotype
of the disease mimicked human BP at the clinical, immuno-
logical and histopathological levels. Titres of BP180/
CXVII-specific antibodies in the peripheral blood of
injected animals correlated well with disease activity. Im-
mune sheep sera showed higher BP180/ CXVII-specific
levels compared to rabbit antibodies and induced more ex-
tensive disease after their passive transfer in mice. This
model provides a solid basis for further pathogenetic stud-
ies in BP and for the development of new therapeutic
approaches.Materials and methods
Mice
Six- to eight-week-old BALB/c mice with a body weight
of approximately 20 g were used. Mice were obtained
from the Cantacuzino Institute (Bucharest, Romania)
and housed at our animal facility. All injections and
bleedings were performed on mice narcotized by admin-
istration of a mixture of ketamine (100 μg/g) and xyla-
zine (15 μg/g). Mice received subcutaneously 10 mg of
ammonium sulfate-precipitated BP180/ CXVII-specific
antibodies from either rabbit (end-titre 12.800-25.600)
or sheep (end-titre 102.400) every second day for two
weeks. Control mice received the same amounts of nor-
mal preimmune rabbit or sheep antibodies, referred to
hereafter as control antibodies. The experiments were
approved by the Ethics Committee (Babes-Bolyai University
Cluj-Napoca no. 1146/2009 and 31458/2010) and per-
formed by qualified personnel.Heterologous expression of murine BP180/ CXVII
fragments
Three extracellular and one intracellular fragments of
murine BP180/ CXVII were expressed as glutathione-S-
transferase (GST) fusion proteins as described [32].
These were designated GST-mCXVII-EC1, GST-
mCXVII-EC3, GST-mCXVII-EC7 and GST-mCXVII-
IC2, and contain murine collagen XVII sequences
stretching from amino acid positions 498–580, 856–901,
1030–1134, and 186–475, respectively. The proteins
were produced using the recombinant vectors pGEX-
mCOL17-EC1, pGEX-mCOL17-EC3, pGEX-mCOL17-
EC7 and pGEX-mCOL17-IC2 in Escherichia coli and
purified by glutathione agarose chromatography [32].
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antibodies
Three New Zealand White rabbits and one sheep were
immunized subcutaneously with either 200 μg or 400 μg,
respectively, of a mixture of the four purified recombinant
fragments of murine type XVII collagen (GST-mCXVII-
EC1, GST-mCXVII-EC3, GST-mCXVII-EC7 and GST-
mCXVII-IC2 in a molar ratio of 2:1:1:1) mixed with
Freund’s complete adjuvant. The animals were boosted
twice with the same protein preparation in incomplete
Freund’s adjuvant at two weeks intervals. Control antibodies
were collected before the first immunization and immune
sera were obtained at regular intervals and characterized by
immunofluorescence (IF) microscopy on cryosections of
murine skin. For the passive transfer experiments, sera from
rabbits were pooled and immunoglobulins were isolated by
ammonium sulfate precipitation. Sheep antibodies were
also subjected to ammonium sulfate precipitation before
passive transfer experiments. Protein concentration was
measured spectrophotometrically at 280 nm [16].Characterization of murine BP180/ CXVII-specific
antibodies
Frozen skin sections were prepared from tissue biopsies
of mice and antibodies against murine BP180/ CXVII
were analyzed by IF microscopy using 100-fold diluted
antibodies specific to rabbit (DakoCytomation) or sheep
IgG (Abcam). Complement-fixing activity of antibodies
to the DEJ was determined as previously described [35].
Recombinant proteins were fractionated by 12.5% and
5% SDS-PAGE, transferred to nitrocellulose, and ana-
lyzed by immunoblotting [16] using HRP-conjugated
secondary antibodies (DakoCytomation) and 3,3’ diami-
nobenzidine (Merck) as a chromogenic substrate.Induction of disease in vivo and phenotype assessment
Mice were examined daily for their general condition and
for evidence of lesions (i.e., erythema, blisters, erosions,
crusts and alopecia). The extent of skin disease (disease ac-
tivity) was scored as follows: 0, no lesions; 1, < 10 lesions
or < 1% of the skin surface; 2, > 10 lesions or 1-5% of the
skin surface; 3, 5-10%; 4, 10-20%; and 5, > 20% involvement
of the skin surface [36]. To evaluate the correlation of anti-
body titres with the extent of disease, sera were obtained
from mice at three different time points (day 0, day 7 and
day 14) and assayed by indirect IF microscopy on frozen
sections of murine skin [37]. Skin biopsies of perilesional
and lesional skin and mucous membranes were obtained at
the end of the observation period and assayed for
immuno-reactants deposition by direct IF and hematoxylin
and eosin staining, respectively. The staining intensity of
immunoreactants in the skin of injected mice was assessed
semi-quantitatively using a score comprising 0, for nostaining; 1, focal, faint staining; 2, faint staining, 3, medium;
and 4, intense staining [36].
Statistical analysis
To estimate the correlation between titres of circulating
antibodies as detected by indirect IF microscopy, and dis-
ease activity, Spearman’s rank correlation test was applied.
Differences in clinical disease activity among groups were
calculated using the Chi-square test. All means are pre-
sented ± s.e.m.
Results
Generation and characterization of BP180/ CXVII-specific
antibodies
Four fragments of murine BP180/ CXVII cloned in a pro-
karyotic expression vector were expressed in E. coli
(Figure 1a). The proteins, purified by glutathione-affinity
chromatography, migrated consistently with their calcu-
lated masses of 37, 32, 39 and 57 kDa when separated by
SDS-PAGE (Figure 1b). Circulating antibodies obtained
from animals immunized with recombinant fragments of
murine BP180/ CXVII were tested for their ability to
recognize the protein in situ and by immunoblotting. Anti-
bodies from both rabbit and sheep showed a linear staining
of the basal membrane by IF microscopy using murine skin
as a substrate (Figures 2a, 2b and Table 1). In contrast,
antibodies obtained before the first immunization did not
bind to the DEJ (Figure 2c). When incubated with 1M
NaCl–split mouse skin, antibodies from immunized rabbits
(Figure 2d) and sheep (Figure 2e) stained the epidermal
side of the substrate. Additionally, sera from immune rab-
bits (Figure 2g) and sheep (Figure 2h), but not control anti-
bodies (not shown) elicited deposition of murine C3 at the
DEJ, as shown by the complement fixation test using mur-
ine skin as a substrate. By immunoblot analysis, antibodies
from immune sera, in contrast to control sera, recognized
recombinant forms of BP180/ CXVII (Figure 2f).
BP180/ CXVII-specific antibodies induce frank skin
blistering when passively transferred into adult mice
The passive transfer of rabbit BP180/ CXVII-specific IgG
resulted in spontaneous blistering even in the absence of
skin rubbing or other investigator manipulations in adult
mice (Figure 3a-c). In mice (n=10) receiving 10 mg/injec-
tion of BP180/ CXVII-specific rabbit IgG lesions first
appeared 9–10 days after the primary injection. In these
mice, initial blisters evolved into erosions partly covered by
crusts on an erythematous background. Mice receiving an
equivalent amount of control rabbit (n=6) or sheep anti-
bodies (n=6) showed no lesions at any time-point during
the observation period (Figure 3d and e, respectively). To
test whether antibodies produced in other species can
transfer the disease, we injected adult mice (Figure 3f) with
10 mg/injection of sheep BP180/ CXVII-specific antibodies
Figure 1 Recombinant fragments of murine BP180/ CXVII.
(a) BP180/ CXVII is composed of an intracellular N-terminal fragment
localized to the hemidesmosomal plaque of basal keratinocytes with
a long extracellular portion containing 15 collagenous domains
(filled rectangles) separated by non-collagenous regions protruding
into the basal membrane. Four fragments of murine type XVII
collagen cDNA cloned in pGEX-6P-1 were expressed in E. coli. Amino
acid positions are shown below each fragment (the diagram is not
at scale). (b) When run on an SDS-PAGE gel the proteins migrated
correspondingly to their calculated molecular weights of 37, 32, 39
and 57 kDa, respectively. In lanes 1 through 6 we loaded: molecular
weight marker, GST, GST-mCXVII-EC1, GST-mCXVII-EC3, GST-mCXVII-
EC7 and GST-mCXVII-IC2. The arrow indicates GST-mCXVII-IC2 at
57kDa and the arrowhead indicates GST at 27kDa.
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and erosions appeared after 5–6 days in mice injected with
these sheep antibodies. Lesions developed at different sites,
including the ears, the snout (Figure 3g), hind limbs
(Figure 3h), abdomen (Figure 3i) and the back (Figure 3j).
In general, more extensive disease developed around the in-
jection sites, but few lesions also developed at distant sites.
Mice injected with BP180/ CXVII-specific antibodies
showed immunopathological features of human BP
At the end of the observation period, mice receiving
pathogenic antibodies and control mice were sacrificed
and biopsies of perilesional skin and oesophagus were
analyzed for immunoreactant deposition. In mice with
clinical signs of disease, we identified linear deposition
of rabbit (Figure 4a) and sheep (Figure 4b) IgG along the
basement membrane of both the skin and oesophagus(not shown). In addition, deposits of complement C3
were detected at the DEJ of mice injected with rabbit
(Figure 4d) and sheep (Figure 4e) BP180/ CXVII-specific
IgG. In contrast, mice receiving control rabbit (not
shown) or sheep antibodies did not show deposition of
IgG (Figure 4c) or mouse C3 (Figure 4f ) in the perile-
sional skin or oesophagus (not shown). Mouse IgG could
be detected in the serum but not in the skin of mice
(not shown).
BP180/ CXVII-specific antibodies induced subepidermal
blistering in vivo
Lesional skin of mice was also obtained at the end of the
observation period and examined for histological signs
of disease by hematoxylin and eosin staining. Subepider-
mal blister formation accompanied by an inflammatory
infiltrate was found in mice receiving either rabbit
(Figure 4g) or sheep (Figure 4h) BP180/ CXVII-specific
IgG. In contrast, histology from mice injected with con-
trol rabbit (not shown) or sheep antibodies (Figure 4i)
showed neither inflammatory cells nor dermal epidermal
separation. Oesophagus specimens from both diseased
or control mice showed no histopathological changes
(not shown).
The extent of skin involvement correlates with levels of
serum BP180/ CXVII-specific antibodies in diseased mice
Blood samples were obtained from mice before the first
injection (day 0) as well as 7, and 14 days later and
assayed by IF microscopy for reactivity to BP180/ CXVII.
The results of this analysis are summarized in Table 2.
By Spearman’s rank correlation test, titres of serum anti-
bodies strongly correlated with the extent of skin disease
both in mice receiving rabbit (r = 0.96) and sheep anti-
bodies respectively (r=0.90). Sheep immune serum
showed higher BP180/ CXVII-specific reactivity com-
pared with rabbit immune sera (Table 1). Accordingly,
mice receiving BP180/ CXVII-specific sheep IgG showed
an earlier onset of disease phenotype and higher scores
at any time point when compared to mice injected with
the same amount of BP180/ CXVII-specific rabbit IgG
whereas mice receiving pre-immune antibodies showed
no clinical phenotype (Figure 5).
Discussion
Different models for bullous pemphigoid have been gener-
ated over the past two decades [14,15,17,19,27]. While the
existing models demonstrated the pathogenicity of BP180/
CXVII-specific antibodies, they have several shortcomings.
Neonatal mice injected with BP180/ CXVII-specific anti-
bodies do not develop frank skin blistering; epidermal
wrinkling and dermal-epidermal separation are induced
by applying pressure (rubbing) on the mouse skin. In
addition, due to their design, the short observation time of
Figure 2 Antibodies from immunized animals recognize mouse BP180/ CXVII and activate complement ex vivo. Serum was obtained
from immunized animals at different time points. Immune rabbit (a) and sheep (b) antibodies bound to the basal membrane of the mouse skin.
In contrast, antibodies obtained from a rabbit before the first immunization (c) did not recognize the antigen in situ. When incubated with mouse
split skin, IgG from the immune sera of both the rabbit (d) and sheep (e) bound to the epidermal side of the 1 NaCl-split skin (magnifications
200x). (f) Pathogenic antibodies in contrast to control antibodies recognized recombinant forms of BP180/ CXVII by immunoblotting; in the left
hand panel: 1, GST and 2, GST-mCXVII-EC1 incubated with immune rabbit serum; 3, GST-mCXVII-EC1 incubated with control rabbit antibodies as a
negative control; in the right hand panel: 4, GST-mCXVII-EC3 and 5, GST-mCXVII-EC7 incubated with immune rabbit serum. BP180/ CXVII-specific
antibodies from the rabbit (g) and sheep (h) activated complement when incubated on cryosections of murine skin (magnifications 200x).
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to reproduce the course of chronic disease and for patho-
genetic studies and development of new therapeutic
approaches. In the present study, to address these draw-
backs, we explored whether the passive transfer of BP180/
CXVII-specific antibodies in adult mice results in blister-
ing in the absence of skin rubbing and allows for longer
observation times. In a first set of experiments, we gener-
ated several fragments of the BP180/ CXVII-specific anti-
bodies, by immunization of rabbits and sheep with the
recombinant autoantigen. Since only about 85% of the BP
sera react with the immunodominant NC16A domain of
BP180/ CXVII by ELISA [38] and most BP sera alsoTable 1 Antibodies to the dermal-epidermal junction
(DEJ) produced for this study
Serum Species Molecular target a IF b CBT c
R1-mCXVII Rabbit BP180/ CXVII 2560 +
R2-mCXVII Rabbit BP180/ CXVII 640 +
R3-mCXVII Rabbit BP180/ CXVII 1280 +
S1-mCXVII Sheep BP180/ CXVII 20480 +
a antibodies were elicited against a mixture of BP180/ CXVII fragments
(see methods).
b titre of indirect immunofluorescence (IF) microscopy on mouse skin sections.
c C3 deposition at the DEJ of mouse skin by the complement binding test (CBT).recognize other epitopes, we injected, antibodies directed
against different fragments of murine BP180 in order to
better reflect the broader autoimmune response against
BP180 in patients. As shown in figure 2, the polyclonal
antibodies generated against recombinant fragments of
the murine protein were able to recognize individual frag-
ments by immunoblotting as well as the native form of
the protein in cryosections of murine skin activating the
complement system, a characteristic feature of several
human and experimental autoimmune blistering diseases
[15,39-41]. Our present model provides a robust system
for further studies dissecting the pathogenic potential of
antibodies against different fragments outside the NC16A
domain, which may arise in patients as a result of an epi-
tope spreading [42].
To test whether mouse BP180/ CXVII-specific anti-
bodies retain their capacity to recognize the basal mem-
brane and to activate complement in vivo, we passively
transferred antibodies from immunized animals or control
antibodies into adult mice. The antibodies bound at the
basement membrane and activated murine complement as
shown by direct IF analysis of perilesional biopsies of the
skin and oesophagus. In addition, they recruited murine
leukocytes and induced skin blistering thus reproducing
the human BP at the clinical, immunological and
Figure 3 BP180/ CXVII-specific antibodies induce blistering skin disease when passively transferred into adult mice. Mice receiving
rabbit antibodies (n=10) to murine BP180/ CXVII developed skin lesions at different sites including the (a) front limbs, the (b) hind limbs and the
(c) ears. In contrast, the ear of a mouse receiving control rabbit antibodies remained unaffected (d) as did a mouse receiving control sheep
antibodies (e). Mice injected with (f) pathogenic sheep antibodies (n=10) presented an even more extensive and generalized disease. Lesions
including erosions partly covered by crusts were recorded on the (g) snout, and (h) hind limb of a mouse receiving sheep antibodies to murine
BP180/ CXVII. More advanced disease was characterized by blisters, erosions and alopecia affecting both the (i) abdomen and the (j) back of mice
injected with sheep BP180/ CXVII-specific IgG.
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similar results of inflammatory blistering in another newly
developed passive antibody transfer model of pemphigoid
disease in which we pre-immunized adult mice with rabbit
IgG followed by injection of collagen XVII-specific rabbitIgG [43]. While having the advantage of an increased in-
flammatory reaction and more extensive disease in mice
compared with the mouse model presented here, the
model reported by Oswald et al., has some limitations due
to the active immunization with the rabbit IgG, which pose
Figure 4 Diseased mice show immuno- and histo-pathological features of the pemphigoid disease. At the end of the observation period,
mice were sacrificed and perilesional biopsies were analyzed for immunoreactants deposition. By IF microscopy, the perilesional skin of a diseased
mouse injected with (a) rabbit or (b) sheep pathogenic antibodies showed linear deposition of murine IgG at the DEJ. Additionally, tissue bound
(d) rabbit and (e) sheep antibodies were shown to activate murine C3 in vivo as revealed by direct IF microscopy. In contrast, no (c) IgG or (f)
complement deposits were found in mice injected with control sheep antibodies. The lesional skin of a mouse receiving (g) rabbit or (h) sheep
BP180/ CXVII-specific IgG shows a dermal-epidermal separation accompanied by an inflammatory infiltrate. In contrast, the skin of a mouse
receiving (i) control sheep antibodies showed no histopathological signs of disease (magnifications, 200x).
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physiology of the pemphigoid disease in patients. Lesions
developed at different sites, including the trunk, head, ears
and the limbs. Extensive erosions were constantly accom-
panied by alopecia. Importantly, disease activity in animals
receiving pathogenic antibodies correlated with the titres
of these antibodies in the sera of injected mice, whereas
control mice showed no clinical disease or circulating anti-
bodies. These observations are in line with studies showing
a correlation between BP180/ CXVII-specific antibody
serum levels and clinical disease in patients [44-46] andTable 2 Titres of antibodies correlate with the extent of disea
Group Antibody a IgG reactivity b
0d 7
1 R a-murine BP180/ CXVII 0 128±13
2 NR IgG 0 0
3 S a-murine BP180/ CXVII 0 640±149
4 NS IgG 0 0
a Adult mice were injected every other day with 10mg of either rabbit Ig (group 1,
groups received similar amounts of control rabbit (group 2, n=6) or sheep (group 4
NS, normal/control sheep.
b End-point titre of IgG reactivity to the basal membrane was assayed by indirect IF
c The extent of skin disease (disease activity) was scored as follows: 0, no lesions; 1,
surface; 3, 5-10%; 4, 10-20%; and 5, >20% involvement of the skin surface.
d Disease activity and IgG titres are presented at as mean ± s.e.m. at day 0, 7 and 1
between antibody titres as detected by IF and disease activity in mice receiving rabtheir potential to induce tissue damage in an ex vivo model
for BP [16]. In the present study, in addition to rabbits we
have also immunized a sheep in order to test for and com-
pare the outcome of the passive transfer of these antibodies
into mice as an alternate source of BP180/ CXVII-specific
antibodies. An unexpected result of our present experi-
ments was the fact that sheep antibodies were much more
suitable for inducing the disease (Figure 5). This may be
due to the higher titre of injected sheep antibodies and/or
to a better in vivo activation of murine innate immune
players, including complement and inflammatory cells. Wese in mice
Disease activity c
14 0 7 14
232±30.3 0 0 1.5±0.17
0 0 0 0
1248±310 0 1±0.15 2.5±0.17
0 0 0 0
n=10) or sheep IgG (group 3, n=10) against murine BP180/ CXVII. Control
, n=6) antibodies. R a-, rabbit anti-; NR, normal/control rabbit; S a-, sheep anti-;
on mouse skin sections.
< 10 lesions or < 1% of the skin surface; 2, > 10 lesions or 1-5% of the skin
4, respectively. Spearman’s rank correlation test showed significant correlation
bit (group 1) or sheep (group 3) pathogenic antibodies.
Figure 5 Anti-murine type XVII collagen antibodies of sheep precipitate the onset and potentiate the outcome of disease. Mice were
injected with antibodies to type XVII collagen generated in rabbits (n=10) and sheep (n=10) respectively. After 9–10 days, first lesions appeared in
mice transferred with antibodies produced in rabbits. In contrast, mice receiving antibodies generated in sheep presented first lesions after 5–6
days. In addition, at each time-point of the observation period, starting with the day of first lesions appearance, the group injected with
pathogenic sheep antibodies had significantly higher disease scores compared to the group injected with pathogenic rabbit anti-mouse collagen
BP180/ CXVII antibodies. Groups injected with either control rabbit (n=6) or sheep (n=6) antibodies did not show any clinical lesions throughout
the observation period. Means are presented ± s.e.m.; *, significance at p < 0.05 by the chi-square test.
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ing and the immune sera showed high titres by indirect IF
microscopy on murine skin sections. Since the serum yield
of a single sheep can be equivalent to that of eight to ten
rabbits, using antibodies generated in sheep may offer a
cost-effective alternative for rabbit IgG. A further major
advantage of the newly developed mouse model of BP is
the fact that it allows for induction of sustained disease
and longer observation times of weeks, which can be likely
extended to months. This could be advantageous in
addressing issues like the specific contribution of different
immune players in disease initiation and progression. Prob-
ably the most striking difference between the neonatal
models and our adult model is represented by the fact that
the total IgG amount/g body weight received by adult mice
is lower and yet they develop disease without the need to
rub their skin. This might be explained at least in part by:
1) the fact that BP is a chronic disease with a complex
pathogenesis in which different immune players act in a se-
quential manner. It is therefore imaginable that limited ob-
servation times preclude some immune players to become
effectively activated for inducing a frank disease in the neo-
natal model; hence not only the dose but also the time
frame of disease induction may play a critical role; 2) the
fact that neonatal mice react differently in terms of activat-
ing immune factors in vivo. It is worth noting in this con-
text, that neonatal mice injected with antibodies to type
VII collagen in the experimental epidermolysis bullosa
acquisita mouse model are resistant to blistering despite
higher-doses of injected antibodies as compared to adult
mice. Susceptibility was rendered in these neonatal miceonly after treatment with IL-8 or C5a, two powerful attrac-
tants for granulocytes [35].
Conclusions
We describe here a model of pemphigoid disease in
adult mice showing sustained blistering upon injection
of BP180/ CXVII-specific antibodies. Pathogenic anti-
bodies for this model may be produced in both sheep
and rabbit. Finally, the present model allows for longer
observation times. Collectively, these features will greatly
facilitate further pathogenetic studies and should prove
helpful for translating this information into novel thera-
peutic strategies for autoantibody-mediated inflamma-
tory diseases.
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